Syndax Pharma rises after H.C. Wainwright starts coverage with 'buy'

Syndax Pharmaceuticals

16/10/2025 11:40

** Shares of cancer therapy maker Syndax Pharmaceuticals SNDX.O rise 1.9% to $15.32 premarket

** H.C. Wainwright starts coverage on SNDX with "buy" rating, sets PT at $40

** SNDX's Revuforj is shaping up to be a key new treatment for a type of aggressive blood cancer called acute myeloid leukemia, H.C. Wainwright says

     ** The new PT represents a 165.9% upside to the stock's last close

    ** Brokerage adds that physicians are increasingly using Revuforj because it works well over time, can be combined with other treatments, and is gaining strong support in real-world use

** The drug is already performing better than expected in the market, with quick insurance coverage and patients staying on it longer - H.C. Wainwright

** Brokerage says "Syndax is emerging as one of the most compelling mid-cap oncology companies in the sector, supported by disciplined execution, expanding visibility, and a clear path toward sustained multi-franchise leadership"

** Up to last close, stock up 13.8% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))